Trabexus is a proprietary†, biocompatible, self-setting, gradually resorbable, calcium phosphate matrix enhanced with partially demineralized allograft particles. Partial demineralization of allograft has been shown to expose key osteoinductive proteins that can influence and direct bone repair.
Trabexus is supplied as a multi-component, sterile, single use kit. After briefly mixing the product components at the point of use, the material will transform into a paste and remain workable for up to 4.5 minutes. Upon setting, the calcium phosphate component will convert to hydroxyapatite, the mineral composition of native human bone. Trabexus is resorbed and remodeled by the body as new bone formation occurs during the healing process.
Trabexus is intended for use to fill bony voids or defects of the skeletal system (i.e. extremities, pelvis) that may be surgically created or osseous defects created from traumatic injury to the bone.
The Optimal BVF
The cornerstone of Trabexus is the thoughtful design of the allograft component. In Trabexus, the allograft component is formed into “hourglass” shapes (known as TRABS®) using a proprietary manufacturing process. This novel shape provides multiple benefits, including increased “interconnectivity” of adjacent particles, creation of channels for accelerated remodeling and greater overall surface area. These factors optimize the ratio of compressive strength to allograft content. The TRABS are partially demineralized, exposing key osteoinductive proteins, while preserving a core of mineralized cortical bone allograft, which further optimizes the product’s resorption characteristics.
|Composition||Resorbable calcium phosphate matrix with partially demineralized allograft particles “TRABS”|
|Compressive Strength||Up to 25MPa|
|Osteoconductive||Material crystallizes into hydroxyapatite upon setting, the mineral phase of native human bone|
|Osteoinductive‡||Allograft component is partially demineralized, exposing key osteoinductive proteins|
|Resorption Profile||More rapid compared to calcium phosphate cements|
|Thermal stability||Does not require refrigeration prior to use|
|Resistant to lavage||Solidifies in a wet field|
|Sizes||3cc, 5cc, 10cc|
†Trabexus is covered by United States patent 9,072,720, with additional patents pending.
‡Allograft component demonstrated osteoinductivity in athymic mouse model submitted for 510(k). Refer to 510(k) summary K143547. Data on file at Vivorté, Inc.